Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $44.6 million.

  • UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) rose 1.65% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 1.65%. This contributed to the annual value of $44.6 million for FY2024, which is 5.00% down from last year.
  • UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) amounted to $44.6 million in FY2024, which was down 5.00% from $47.0 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) registered a high of $47.0 million during FY2023, and its lowest value of $44.4 million during FY2020.
  • For the 3-year period, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) averaged around $45.7 million, with its median value being $45.6 million (2022).
  • In the last 5 years, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) climbed by 3.11% in 2023 and then declined by 5.00% in 2024.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) stood at $44.4 million in 2020, then rose by 1.34% to $45.0 million in 2021, then climbed by 1.20% to $45.6 million in 2022, then grew by 3.11% to $47.0 million in 2023, then decreased by 5.00% to $44.6 million in 2024.